Physician profile
Nikki Oneill
NPI 1609367226
$439.21
in general payments reported to CMS, 2019-2025
13 companies · $17.84 in 2025
The $17.84 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.56 · 2023: $121 · 2024: $255 · 2025: $17.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $113.42 | 2024 | |
| Mayne Pharma Commercial LLC | $61.39 | 2022-2023 | |
| Shield Therapeutics INC | $59.86 | 2024 | |
| Abbvie INC. | $47.51 | 2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Exeltis, USA INC. | $28.06 | 2022-2023 | Slynd |
| Millicent US INC | $19.91 | 2024 | Intrarosa, Femring |
| Lilly USA, LLC | $17.98 | 2024 | Zepbound |
| Stryker Corporation | $17.84 | 2025 | Clottriever Bold Catheter |
| Novo Nordisk INC | $15.65 | 2024 | Wegovy |
| Pfizer INC. | $15.27 | 2024 | |
| Urovant Sciences INC | $14.71 | 2022 | |
| Agile Therapeutics, INC. | $14.28 | 2023 | Twirla |
| Astellas Pharma US INC | $13.33 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikki Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.